X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (533) 533
humans (499) 499
female (329) 329
male (320) 320
middle aged (225) 225
adult (216) 216
psychiatry (193) 193
12-month prevalence (169) 169
aged (156) 156
treatment outcome (133) 133
12-month outcomes (117) 117
ophthalmology (114) 114
sustained benefits (105) 105
adolescent (103) 103
12-month follow-up (102) 102
prevalence (100) 100
ranibizumab (90) 90
12-month (88) 88
young adult (87) 87
united-states (74) 74
comorbidity (73) 73
depression (71) 71
phase-iii (70) 70
analysis (68) 68
risk factors (67) 67
article (65) 65
epidemiology (62) 62
follow-up studies (61) 61
time factors (61) 61
care and treatment (60) 60
intravitreal injections (59) 59
substance abuse (58) 58
psychiatric-disorders (57) 57
aged, 80 and over (56) 56
abridged index medicus (55) 55
12-month-old infants (48) 48
psychology (47) 47
clinical neurology (46) 46
retrospective studies (46) 46
vascular endothelial growth factor a - antagonists & inhibitors (46) 46
macular edema - drug therapy (45) 45
research (45) 45
retinal vein occlusion - drug therapy (45) 45
bipolar disorder (44) 44
infants (44) 44
bevacizumab (43) 43
macular edema (43) 43
mental disorders (43) 43
psychology, clinical (43) 43
surveys and questionnaires (43) 43
mental health (42) 42
prospective studies (42) 42
retinal vein occlusion (42) 42
psychology, developmental (40) 40
anxiety (39) 39
efficacy (39) 39
public, environmental & occupational health (39) 39
cross-sectional studies (38) 38
risk-factors (38) 38
studies (38) 38
vascular endothelial growth factor (38) 38
angiogenesis inhibitors - therapeutic use (37) 37
endothelial growth-factor (37) 37
health surveys (36) 36
medical research (36) 36
mental disorders - epidemiology (36) 36
national-comorbidity-survey (36) 36
psychology, experimental (36) 36
cardiac & cardiovascular systems (35) 35
infant (35) 35
clinical trials (34) 34
pharmacology & pharmacy (34) 34
surgery (34) 34
therapy (34) 34
visual acuity (34) 34
alcohol use (33) 33
retinal vein occlusion - complications (32) 32
patients (31) 31
sex factors (31) 31
tomography, optical coherence (31) 31
adults (30) 30
double-blind (30) 30
macular edema - etiology (30) 30
substance use disorders (30) 30
anxiety disorders (29) 29
disorders (29) 29
macular degeneration (29) 29
medicine & public health (29) 29
psychiatric status rating scales (29) 29
safety (29) 29
age factors (28) 28
children (28) 28
health aspects (28) 28
babies (27) 27
branch (27) 27
child development (27) 27
drug therapy (27) 27
eye diseases (27) 27
medicine, experimental (27) 27
quality-of-life (27) 27
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Brain Injury, ISSN 0269-9052, 08/2015, Volume 29, Issue 10, pp. 1175 - 1181
Objective: To examine impulsivity changes after a severe traumatic brain injury (TBI) and to explore the relationships between impulsivity dimensions (urgency,... 
neurobehavioural changes | UPPS Impulsive Behaviour Scale | 12-month outcome | MODERATE | HEAD-INJURY | MULTIDIMENSIONAL APPROACH | IMPLEMENTATION INTENTIONS | NEUROSCIENCES | INHIBITION | DECISION-MAKING | DISEASE | IMPAIRMENTS | REHABILITATION | SCALE | VALIDITY
Journal Article
Journal Article
OPHTHALMOLOGY, ISSN 0161-6420, 10/2016, Volume 123, Issue 10, pp. S78 - S88
The association of retinal hypoxia with retinal neovascularization has been recognized for decades, causing Michaelson to postulate in 1948 that a factor... 
OCCLUSION 12-MONTH OUTCOMES | 2.0 MG RANIBIZUMAB | PROLIFERATIVE DIABETIC-RETINOPATHY | MACULAR EDEMA SECONDARY | INTRAVITREAL AFLIBERCEPT INJECTION | LONG-TERM OUTCOMES | OPHTHALMOLOGY | VEIN OCCLUSION | VEGF TRAP-EYE | CHOROIDAL NEOVASCULARIZATION | BEVACIZUMAB AVASTIN THERAPY
Journal Article
Journal of Nephrology, ISSN 1121-8428, 09/2011, Volume 24, Issue 5, pp. 613 - 618
Journal Article
Journal Article
Journal Article
Journal Article
Ophthalmology, ISSN 0161-6420, 12/2017, Volume 124, Issue 12, pp. 1778 - 1787
To evaluate the long-term (24-month) efficacy and safety of ranibizumab 0.5 mg administered pro re nata (PRN) with or without laser using an individualized... 
TRIAL | MACULAR EDEMA | PHASE-III | OPHTHALMOLOGY | STABILIZATION CRITERIA | DRIVEN | 12-MONTH OUTCOMES
Journal Article